Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Pfizer’s spoiler on Johnson & Johnson’s earnings rally

Tuesday, October 18, 2016 13:22
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The world’s largest healthcare company Johnson & Johnson’s (NYSE:JNJ) third-quarter earnings per share came in 3 cents higher than analysts’ forecasts.

J&J came in two cents above estimates with adjusted third quarter profit of $1.68 per share and with revenue beating the street forecast as well. The company raised its full-year forecast, thanks in part to increased drug sales.

But it wasn’t a good day for the stock, which ended down after rival drugs group Pfizer (NYSE:PFE) announced overnight said it would release a cheaper version of JNJ’s immune drug Remicade – before offering the knock-out blow on Tuesday when it confirmed its Inflectra injection, a biosimilar version of Johnson & Johnson’s JNJ blockbuster drug Remicade, will be available in the US in late November.

Pfizer also enumerated that its drug would be 15% cheaper than J&J’s current wholesale prices.

With annual US sales of $5bn and its wide use to also treat Crohn’s disease and psoriasis, Remicade is J&J’s biggest product. Biosimilar drugs are close copies intended to provide savings compared with costly branded products. Inflectra is already available in Europe.

But Pfizer is playing for high stakes in the US backyard for both companies. J&J is appealing an August federal court decision that invalidated a US Remicade patent, setting the stage for a February court battle with Pfizer. Should Pfizer launch Inflectra and later lose the court fight, that could entitle J&J to triple damages.

In the meantime, analysts predicted US Remicade sales will fall 15 to 20% in 2017 – even though J&J on Tuesday predicted the vast majority of patients taking Remicade are unlikely to switch to a biosimilar.

Of course, should US voters opt to elect drug price crusader Hillary Clinton as the next White House occupant next month, the spat between J&J and Pfizer may be compared with re-arranging the deck chairs on the Titanic ship.

J&J shares closed down 2.6% at $115.39 while Pfizer was up 0.6% at $32.69 on Tuesday.

Story by ProactiveInvestors

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.